You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Non-intrusive detection of temporary neurologic impairment by opioids

    SBC: Zxerex Corporation            Topic: NIDA

    PROJECT SUMMARY With the exception of the Breathalyzer for alcoholthere is currently no available technology that can immediately identify neurologic impairment related to the use of licit or illicit drugsThe illicit use of opioids in particular currently represents a nation wide health crisiswith an estimatedmillion Americans misusing opioids inThe presently available methods for detecting opioid ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A New Small-Molecule Kinase Inhibitor for Airway Disease

    SBC: NuPeak Therapeutics, Inc.            Topic: NHLBI

    Abstract NuPeak Therapeutics Incis a biotechnology companyC corporationdesigned to deliver a first in class smallmolecule kinase inhibitorSMKIfor therapeutic use in humansThe present Project is aimed at an inhibitor for treatment of respiratory airway disease especially due to asthma and COPDwhich remain leading causes of morbidity and mortality in the U Sand worldwide despite current therapeutic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain

    SBC: Regulonix            Topic: NIDA

    ABSTRACT Chemotherapy induced peripheral neuropathyCIPNis a commonprevalenceand potentially doselimiting side effect of many cancer chemotherapy drug treatment regimensClinicallyCIPN presents with pain that is burningshooting or electric shock likeThe increase in prevalence of cancer coupled with an increase in the cancer survival rates due to chemotherapy regimens is transforming cancer pain into ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Visual biofeedback to reduce head motion during MRI scans

    SBC: Nous Imaging, Inc.            Topic: 101

    Project Abstract Summary The goal of this STTR application is to deliver a brain MRI technology that feeds back head motion measurements derived from our Framewise Integrated Real Time MRI MonitoringFIRMMto MRI scan participants in order to reduce head motion via behavioral trainingBecause MRI scanning produces highresolution images and does not expose patients to radiationit has become an immense ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Fourth Trimester- A web-based tool for Postpartum Care to Address the Needs of Underserved Women

    SBC: Orange Square Design, Inc.            Topic: NIMHD

    PROJECT SUMMARY ABSTRACT In the United Statesthe postpartum period is a critical time for both maternal and child healththe mortality rate is the highest among other developedhigh income countries and more than half of all maternal deaths occur postpartumfrom one day to one year after birthThis poor outcome is linked to the racial and ethnic disparities that disproportionately effect black women w ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody

    SBC: APT THERAPEUTICS, INC.            Topic: 100

    Principal Investigator Program DirectorLastFirstMiddleChenRidong Abstract InterleukinILimmunotherapy can result in remarkable long term responses in some cancer patients by stimulating the immune response to kill tumor cellsHowevercurrent rILtherapy is limited to highly selected patients due to its requirements for high and frequent dosingwhich can result in severe side effectsMoreoverrILalso acti ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Novel formulations of Allopregnanolone to treat Alzheimer's Disease

    SBC: Proneurogen, Inc            Topic: NIA

    PROJECT SUMMARY ABSTRACT Alzheimer s diseaseADis a progressive multifactorial disease affecting more thanmillion people worldwide and is the most common dementia of late lifeTo dateno interventions have demonstrated substantial therapeutic efficacy to preventdelay or treat ADCurrent thinking in the field embraces the complexity of AD pathophysiologywhich has enabled a more diverse therapeutic pipe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists to prevent Charcot Marie Tooth diseaseA Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractCharcot Marie ToothCMTdisease typeA is an incurableprimarily pediatricautosomal dominant neuromuscular degenerative disease caused by mutations in the mitofusinMFNgeneThere are currently no disease altering treatmentsMitochondria in Mot ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A mobile technology to extend the reach of primary care for opioid misuse

    SBC: Rissana, LLC            Topic: NIDA

    Project Summary Opioid use disorderOUDhas reached epidemic levels in the United Stateswith catastrophic resultsmore Americans died from opioid overdoses inandthan in the entirety of the Vietnam WarPrimary care providersPCPsserve a critical role in combatting this epidemicbecause they see patients who misuse opioids but are not yet dependent in addition to those who are already dependentHoweverther ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK)

    SBC: Faknostics, LLC            Topic: 102

    PROJECT SUMMARY ABSTRACT Focal Adhesion KinaseFAKis a major cancer drug target that is overexpressed in multiple tumor typesFAK is a critical regulator of tumor survivalinvasionproliferationmetastasisand immune evasionCurrent FAK inhibitors that target the ATP binding pocket of the kinase domain do no effectively inhibit FAK in cancer because FAK also functions as a scaffolding proteinThe Focal Ad ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government